These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 32246277)
41. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives]. Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886 [TBL] [Abstract][Full Text] [Related]
42. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Shergold AL; Millar R; Nibbs RJB Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806 [TBL] [Abstract][Full Text] [Related]
43. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
44. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy. Shi Y; Li D; He C; Chen X Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152 [TBL] [Abstract][Full Text] [Related]
45. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061 [TBL] [Abstract][Full Text] [Related]
46. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017 [TBL] [Abstract][Full Text] [Related]
47. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Gandini S; Massi D; Mandalà M Crit Rev Oncol Hematol; 2016 Apr; 100():88-98. PubMed ID: 26895815 [TBL] [Abstract][Full Text] [Related]
49. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743 [TBL] [Abstract][Full Text] [Related]
50. [Radiotherapy and PD-L1 Expression]. Sato H; Okonogi N; Yoshimoto Y; Tamaki T; Suzuki Y Gan To Kagaku Ryoho; 2019 May; 46(5):845-849. PubMed ID: 31189801 [TBL] [Abstract][Full Text] [Related]
51. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Bertucci F; Gonçalves A Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073 [TBL] [Abstract][Full Text] [Related]
52. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286 [TBL] [Abstract][Full Text] [Related]
53. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587 [TBL] [Abstract][Full Text] [Related]
54. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088 [TBL] [Abstract][Full Text] [Related]
55. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Constantinidou A; Alifieris C; Trafalis DT Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773 [TBL] [Abstract][Full Text] [Related]
56. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371 [TBL] [Abstract][Full Text] [Related]
57. Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV Front Immunol; 2018; 9():2204. PubMed ID: 30319648 [TBL] [Abstract][Full Text] [Related]
58. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
59. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259 [TBL] [Abstract][Full Text] [Related]
60. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]